Press Releases

CPHI & PMEC China will open in June (19-21st) at the Shanghai New International Expo Center as international audiences return in search of regional ingredient suppliers. In total, over 55,000 attendee visits are expected at an event that has returned to its pre-pandemic scale with over 200,000sqm of exhibition space. China opened-up to international visitors again in March  and is expected to see surging demand for domestic-international partnering. One of the prima

XNK Therapeutics AB today announced that the company's autologous natural killer cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company. The preclinical validation study aims to test the cell therapy candidate XNK04 alone and in combination with an antibody checkpoint inhibitor against autologous cancer cells isolated from patients with hepatocellular carcinoma (

Galmed Pharmaceuticals Ltd. reported today the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M. The agreement provides Galmed with a minority, but a strategic stake in Onkai. Concurrently, a strategic partnership agreement is being signed to advance both companies by leveraging their complementary knowledge and experience in their respective fields. OnKai, a US-based technology company, combines public healthcare and

SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake's Nanobody® sonelokimab based on SHL Medical's Molly® autoinjector technology. Sonelokimab is MoonLake Immunotherape

Sound Pharmaceuticals is pleased to announce that it has completed enrollment in its first Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory, for the treatment of Meniere's Disease (STOPMD-3). SPI-1005 is given orally and is the only drug demonstrated to improve both hearing loss and tinnitus in Meniere's Disease (MD) patients following 3 to 4 weeks of treatment in two prior randomized double-blind placebo-controlled trials (RCT) involving over 165 patients. The STO

Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty' (code name: CP-COV03). In the announcement, Hyundai Bioscience shared its plans to proceeding emergency use approval (hereafter, EUA) and approval process with the Korean Ministry of Food and Drug Safety (MFDS). Hyundai Bioscience plans to pursue other feasible fast-track processes for Xafty in oversea countries as well

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished the process transfer and GMP supply of FGF-1 candidate. 3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP ma

CPHI & PMEC China will open in June (19-21st) at the Shanghai New International Expo Center as international audiences return in search of regional ingredient suppliers. In total, over 55,000 attendee visits are expected at an event that has returned to its pre-pandemic scale with over 200,000sqm of exhibition space. China opened-up to international visitors again in March[1] and is expected to see surging demand for domestic-international partnering. One of the primary reasons

Kiromic BioPharma, Inc., a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today announces that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).

Charles River Laboratories International, Inc. announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix® NGS). Accugenix NGS simultaneously sequences millions of individual DNA fragments from a sample and provides key information to pharmaceutical and personal care manufacturers regarding microbial control. When studying pure isolates and/or sequencing of mixed species environments, Accugenix NGS provides